FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
FibroBiologics presented preclinical data at the NASS 2026 Annual Meeting showing its fibroblast spheroid-derived chondrocyte (FSdC) spheroids preserved disc height better than any other fibroblast-based approach tested in a 12-week rabbit model of degenerative disc disease. At 12 weeks, normalized disc height index was 80.7% for FSdC spheroids versus 71.8% in controls, with statistically significant improvements across all three fibroblast-treated groups.
Key figures
- Drug Name
- FSdC spheroids (fibroblast spheroid-derived chondrocytes)
- Phase Of Trial
- Preclinical (12-week rabbit model of degenerative disc disease)
- Dhi 12 week fsdc
- 80.7%
- Dhi 12 week control
- 71.8%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.